サインイン

Noa Kaynan

Preclinical Research Department

Novocure Ltd., Haifa, Israel

BIOGRAPHY

Noa Kaynan has not added Biography.

If you are Noa Kaynan and would like to personalize this page please email our Author Liaison for assistance.

PUBLICATIONS

The viral KSHV chemokine vMIP-II inhibits the migration of Naive and activated human NK cells by antagonizing two distinct chemokine receptors.

PLoS pathogens Aug, 2013 | Pubmed ID: 23966863

Cytokine secretion and NK cell activity in human ADAM17 deficiency.

Oncotarget Dec, 2015 | Pubmed ID: 26683521

Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection.

The Journal of experimental medicine Aug, 2016 | Pubmed ID: 27503073

INSTITUTIONS

Novocure Ltd., Haifa, Israel

JOVE ARTICLES

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)

Yaara Porat¹,

Moshe Giladi¹,

Rosa S. Schneiderman¹,

Roni Blat¹,

Anna Shteingauz¹,

Einav Zeevi¹,

Mijal Munster¹,

Tali Voloshin¹,

Noa Kaynan¹,

Orna Tal¹,

Eilon D. Kirson²,

Uri Weinberg³,

Yoram Palti²

¹Preclinical Research Department, Novocure Ltd., Haifa, Israel,

², Novocure Ltd., Haifa, Israel,

³, Novocure GmbH, Lucerne, Switzerland

Cancer Research

個人情報保護方針

利用規約

一般データ保護規則

お問い合わせ

図書館への推薦

JoVE ニュースレター

研究

JoVE Journal
メソッドコレクション
JoVE Encyclopedia of Experiments
アーカイブ

教育

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
教員向けリソースセンター
教員用サイト

著者

概要
出版プロセス
編集委員会
スコープと指針
査読
よくある質問
お申し込み

図書館員

概要
お客様の声
定期購読
アクセス
リソース
図書館諮問委員会
よくある質問

JoVEについて

概要
経営陣
ブログ
JoVE Help Center

Noa Kaynan

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Preclinical Research Department

Novocure Ltd., Haifa, Israel

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)

Preclinical Research Department